Glurenorm® [Gliquidone]
Boehringer Ingelheim
1490 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Hypoglycemic.
Glurenorm stimulates insulin production by beta cells of the pancreas.
Indications
Type 2 diabetes mellitus (non-insulin-dependent) in middle-aged and elderly patients with poor diet therapy.
Composition
1 tablet contains glycvidone 30 mg.
Excipients: lactose monohydrate - 134.6 mg, dried corn starch - 70 mg, soluble corn starch - 5 mg, magnesium stearate - 0.4 mg.
No customer reviews for the moment.
Dosage and Administration
The drug is administered orally. You must comply with the recommendations of the doctor regarding the dose of the drug and diet. Do not stop taking the drug without consulting a doctor.
The initial dose of Glyurenorm is usually 1/2 tab. (15 mg) at breakfast. The drug must be taken at the beginning of the meal. After taking Glyurenorm, food intake should not be missed.
If taking 1/2 tab. (15 mg) does not lead to adequate improvement, after consultation with the doctor, the dose should be gradually increased. If the daily dose of Glyurenorm does not exceed 2 tab. (60 mg), it can be administered in 1 reception, during breakfast.
When prescribing a higher dose, the best effect can be achieved when taking a daily dose, divided into 2-3 doses. In this case, the highest dose should be taken at breakfast. Increasing the dose of more than 4 tab. (120 mg) / day usually does not lead to a further increase in efficacy.
The maximum daily dose - 4 tab. (120 mg).
Patients with impaired renal function
About 5% of the drug metabolites are excreted by the kidneys. In patients with impaired renal function, dose adjustment is not required.
Patients with impaired liver function
Taking a dose in excess of 75 mg in patients with impaired liver function requires careful monitoring of the patient's condition. The drug should not be prescribed to patients with severely impaired liver function, because 95% of the dose is metabolized in the liver and excreted through the intestines.
Combination therapy
With insufficient clinical effect of monotherapy with Glyurenorm®, only the additional prescription of metformin can be recommended.
Adverse reactions
From the hemopoietic system: thrombocytopenia, leukopenia, agranulocytosis.
Metabolism: hypoglycemia.
From the nervous system: headache, dizziness, drowsiness, paresthesia, fatigue.
On the part of the organ of vision: accommodation disturbances.
Since the cardiovascular system: angina, extrasystole, cardiovascular failure, hypotension.
On the part of the digestive system: decreased appetite, nausea, vomiting, constipation, diarrhea, discomfort in the abdomen, dry mouth, cholestasis.
On the part of the skin and subcutaneous tissue: rash, itching, urticaria, Stevens-Johnson syndrome, photosensitivity reaction.
Others: chest pain.
Contraindications
Hypersensitivity (including to sulfonylurea derivatives or sulfonamides), type 1 diabetes mellitus (insulin-dependent), diabetic acidosis, ketoacidosis, precoma, coma, pregnancy, breast-feeding.
Drug interactions
It is possible to strengthen , insulin and oral hypoglycemic agents.
Beta-blockers, sympatholytics (including clonidine), reserpine, and guanethidine can enhance the hypoglycemic effect and simultaneously mask the symptoms of hypoglycemia.
Perhaps a decrease in hypoglycemic action with the simultaneous appointment of glycvidone and aminoglutetimid, sympathomimetics, GCS, thyroid hormones, glucagon, thiazide and "loop" diuretics, oral contraceptives, diazoxide, phenothiazine and drugs containing nicotinic acid.
Barbiturates, rifampicin and phenytoin can also reduce the hypoglycemic effect of glycvidone.
Enhancing or weakening the hypoglycemic effect of glycvidone has been described when taking histamine H2 receptor blockers (cimetidine, ranitidine) and ethanol.
Pregnancy and Lactation
There are no data on the use of glycvidon in women during pregnancy and breastfeeding.
It is not known whether glycvidone or its metabolites penetrate into breast milk. In pregnant women with diabetes mellitus, careful monitoring of plasma glucose concentration is necessary. Reception of oral antidiabetic agents in pregnant women does not provide adequate control of the level of carbohydrate metabolism. Therefore, the use of the drug Glyurenorm® during pregnancy and lactation is contraindicated.
In the event of pregnancy or when planning pregnancy during the use of the drug Glyurenorm®, the drug should be canceled and switched to insulin.
Special instructions
Glurenorm should not replace a therapeutic diet that allows you to control the patient’s body weight and reduce the risk of cardiovascular disorders.
Overdosage
An overdose of sulfonylurea derivatives can lead to hypoglycemia.
Symptoms: tachycardia, increased sweating, hunger, heartbeat, tremor, headache, insomnia, irritability, impaired speech and vision, motor restlessness and loss of consciousness.
Treatment: If symptoms of hypoglycemia occur, glucose (dextrose) or foods rich in carbohydrates should be ingested. In severe hypoglycemia (loss of consciousness, coma), dextrose is administered IV. After the recovery of consciousness, the intake of easily digestible carbohydrates (in order to avoid the repeated development of hypoglycemia).
- High-performance Liquid Chromatographic Analysis of Pioglitazone, Gliquidone, Rosuvastatin and Simvastatin in Formulations and Human Serum
- Extrapancreatic action of the sulphonylurea gliquidone: post-receptor effect on insulin-stimulated glycogen synthesis in rat hepatocytes in primary culture
- Diabetic control with gliquidone — A short acting sulphonylurea
- Preparation and dissolution rate of gliquidone-PVP K30 solid dispersions
- Drug interaction studies of gliquidone with fexofenadine, cetirizine, and levocetirizine
- Preparation and spectroscopic characterization of metal complexes of gliquidone
- Validated HPLC Method for the Determination of Gliquidone in Rat Plasma
- Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations
- The effect of Glurenorm (gliquidone) on lenses and skin in experimental diabetes
- Glibenclamide and Gliquidone in the Treatment of Non-Insulin-Dependent Diabetes Mellitus
- Extrapancreatic action of sulphonylureas: effect of gliquidone on insulin and glucagon binding to rat liver plasma membranes
- The non-sulfonylurea moiety of gliquidone mimics the effects of the parent molecule on pancreatic B-cells
- Gliquidone, an ATP-dependent K+ channel antagonist, antagonizes morphine-induced hypermotility
- Effects of gliquidone and glibenclamide on metabolic response and insulin receptor interaction in monocytes from patients with type 2 diabetes mellitus
- PHARMACOLOGY OF THE HYPOGLYCAEMIC SULPHONYLUREA GLIQUIDONE III. CONFORMATIONAL ANALYSIS
- Spectroscopic study to characterize in vitro interaction of losartan with gliquidone and pioglitazone
- Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function
- Potentiation of the insulinotropic and hypoglycemic action of gliquidone by succinic acid esters
- Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human
- Pharmacokinetics and hepatic uptake of gliquidone affected by Huangqi injection
- Gliquidone decreases urinary protein by promoting tubular reabsorption in diabetic Goto-Kakizaki rats
- Simultaneous Determination of Gliquidone, Fexofenadine, Buclizine, and Levocetirizine in Dosage Formulation and Human Serum by RP-HPLC
- Gliquidone
- PHARMACOKINETICS OF GLIQUIDONE
8 other products in the same category:
arrow_upward